NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
![Cover of Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews](/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-dare-lrg.png)
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsCRD summary
This review evaluated efficacy, safety and tolerability of probiotics in irritable bowel syndrome and concluded that Bifidobacteriuminfantis 35624 showed efficacy in improving symptoms; data for other probiotics were inadequate. The conclusion that evidence on probiotics was of poor quality appeared appropriate, although conclusions about the efficacy of B. infantis may be less reliable.
Authors' objectives
To evaluate efficacy, safety and tolerability of probiotics in treatment of irritable bowel syndrome (IBS).
Searching
MEDLINE, PubMed, EMBASE and The Cochrane Library were searched from inception to June 2008 to identify relevant articles published in English. Search terms were reported. Abstracts from Digestive Disease Week, annual meeting of American College of Gastroenterology and United European Gastroenterology Week were searched from 2001 to 2007. Reference lists of retrieved studies and relevant reviews and guidelines were searched.
Study selection
Randomised placebo-controlled trials (RCTs) that evaluated single or combination probiotics in patients with IBS (defined by Manning or Rome II criteria) and that reported IBS symptoms, adverse events or tolerability were eligible for inclusion in the review.
Included studies evaluated 13 different probiotics or combinations of probiotics. Where reported, mean age of patients who received probiotics ranged from 38 to 51 years and the proportion of female patients ranged from 56% to 100%
Two reviewers independently selected studies for inclusion. Disagreements were resolved by consensus.
Assessment of study quality
The validity of studies was assessed using the Rome II methodology scale (studies receive up to 14 points for trial design).
The authors did not state how many reviewers performed the assessment.
Data extraction
The authors directly extracted outcome data from the included studies, but did not state how many reviewers performed the extraction.
Methods of synthesis
Studies were combined in a narrative synthesis grouped by probiotic.
Results of the review
Sixteen RCTs (n=1,342) met the inclusion criteria. Studies scored between 5 and 12 points on the Rome II methodology scale. Eleven studies were considered to be of suboptimal design (precise definition of suboptimal was not clear).
Two of the appropriately-designed RCTs evaluated Bifidobacterium infantis 35624 and reported statistically significant improvements in abdominal pain/discomfort, bloating/distension and/or bowel movement relative to placebo (p<0.05). In these two trials B. infantis 35624 was given daily for four or eight weeks as 1x1010 live cells in malted milk drink or 1x106, 1x108 or 1x1010 colony forming units per millilitre in capsule form. None of the other studies described as appropriately designed showed significant improvements in IBS symptoms.
No studies reported quantifiable data on relative tolerability or adverse events.
Authors' conclusions
B. infantis 35624 showed efficacy in terms of improvement in IBS symptoms. There were inadequate data on efficacy or adverse effects of other probiotics in IBS.
CRD commentary
The review was based on a question clearly defined in terms of the participants, interventions, controls, outcomes and study designs of interest. Several electronic and other sources were searched for relevant articles. Limiting the search to published English-language studies meant that language and publication biases could not be ruled out. Attempts were made to minimise potential for errors and bias in study selection; it was unclear whether this was the case for other review processes. Validity of included studies was assessed using an established method, although the threshold at which studies were considered to be of adequate quality was unclear and there may be potential for bias in this process. The authors conclusion that most of the evidence for probiotics was of inadequate quality appeared appropriate; their specific conclusion about efficacy of B. infantis may be less reliable.
Implications of the review for practice and research
The authors did not make any recommendations for practice.
Research: The authors stated that further studies of probiotics other than B. infantis were needed and these should adhere to the Rome III guidelines on the design of gastrointestinal disorder trials. They added that further studies to assess longevity of response were needed.
Funding
None stated.
Bibliographic details
Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. American Journal of Gastroenterology 2009; 104(4): 1033-1049. [PubMed: 19277023]
Original Paper URL
http://www.nature.com/ajg/journal/v104/n4/abs/ajg200925a.html
Indexing Status
Subject indexing assigned by NLM
MeSH
Bifidobacterium; Humans; Irritable Bowel Syndrome /drug therapy; Probiotics /therapeutic use; Treatment Outcome
AccessionNumber
Database entry date
31/03/2010
Record Status
This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results and conclusions followed by a detailed critical assessment on the reliability of the review and the conclusions drawn.
- CRD summary
- Authors' objectives
- Searching
- Study selection
- Assessment of study quality
- Data extraction
- Methods of synthesis
- Results of the review
- Authors' conclusions
- CRD commentary
- Implications of the review for practice and research
- Funding
- Bibliographic details
- Original Paper URL
- Indexing Status
- MeSH
- AccessionNumber
- Database entry date
- Record Status
- Review Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.[Curr Med Res Opin. 2017]Review Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Curr Med Res Opin. 2017 Jul; 33(7):1191-1197. Epub 2017 Mar 7.
- Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.[Am J Gastroenterol. 2006]Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM. Am J Gastroenterol. 2006 Jul; 101(7):1581-90.
- Efficacy and safety of probiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis of randomised clinical trials using ROME IV criteria.[Clin Nutr. 2023]Efficacy and safety of probiotics in the treatment of irritable bowel syndrome: A systematic review and meta-analysis of randomised clinical trials using ROME IV criteria.Konstantis G, Efstathiou S, Pourzitaki C, Kitsikidou E, Germanidis G, Chourdakis M. Clin Nutr. 2023 May; 42(5):800-809. Epub 2023 Mar 31.
- Review Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.[World J Gastroenterol. 2015]Review Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.Didari T, Mozaffari S, Nikfar S, Abdollahi M. World J Gastroenterol. 2015 Mar 14; 21(10):3072-84.
- Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.[J Gastroenterol Hepatol. 2014]Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, et al. J Gastroenterol Hepatol. 2014 Jan; 29(1):52-9.
- The utility of probiotics in the treatment of irritable bowel syndrome: a system...The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...